The DOI matches its Crossref record; 166 of the 166 references it cites were found in a registry or an index.
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationVogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationFinal Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,602
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Self-citationSafety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Self-citationMutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Self-citationWolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
Genomic classification of cutaneous melanoma
Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B., Arachchi, H., Arora, A., Auman, J. T., Ayala, B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.044 · Cited by 3,151
Self-citationHauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Self-citationMechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
A cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751
Distinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
Self-citationWeber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Andtbacka, R. H. I., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K. A., Spitler, L. E., Puzanov, I., Agarwala, S. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3377 · Cited by 2,634
A landscape of driver mutations in melanoma
Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
Self-citationSchadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
Larkin, J., Ascierto, P. A., Dréno, B., Atkinson, V., Liszkay, G., Maio, M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408868 · Cited by 2,068
Self-citationAtkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G., Margolin, K., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2105 · Cited by 2,048
Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W., Zhang, C., Zhang, Y., Habets, G., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,831
Self-citationRAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M., & Rosen, N. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,811
Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hatzivassiliou, G., Song, K., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,622
Somatic Activation of KIT in Distinct Subtypes of Melanoma
Curtin, J. A., Busam, K., Pinkel, D., & Bastian, B. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2984 · Cited by 1,616
Ribas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F. S., Schachter, J., Pavlick, A. C., Lewis, K. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00083-2 · Cited by 1,572
Self-citationLoss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Heidorn, S. J., Milagre, C., Whittaker, S., Nourry, A., Niculescu-Duvas, I., Dhomen, N., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,465
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415
Long, G. V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J.-J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60898-4 · Cited by 1,399
Self-citationPrimary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337
Self-citationImproved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-63198 · Cited by 1,330
Self-citationBrafV600E cooperates with Pten loss to induce metastatic melanoma
Dankort, D., Curley, D. P., Cartlidge, R. A., Nelson, B., Karnezis, A. N., Damsky Jr, W. E., You, M. J., DePinho, R. A., McMahon, M., & Bosenberg, M. (2009) · Nature Genetics · doi:10.1038/ng.356 · Cited by 1,189
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment
Harlin, H., Meng, Y., Peterson, A. C., Zha, Y., Tretiakova, M., Slingluff, C., McKee, M., & Gajewski, T. F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2281 · Cited by 1,121
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Margolin, K., Ernstoff, M. S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., Wolchok, J. D., Clark, J. I., Sznol, M., Logan, T. F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70090-6 · Cited by 1,091
The Genetic Evolution of Melanoma from Precursor Lesions
Shain, A. H., Yeh, I., Kovalyshyn, I., Sriharan, A., Talevich, E., Gagnon, A., Dummer, R., North, J., Pincus, L., Ruben, B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502583 · Cited by 1,065
Horvat, T. Z., Adel, N. G., Dang, T.-O., Momtaz, P., Postow, M. A., Callahan, M. K., Carvajal, R. D., Dickson, M. A., D'Angelo, S. P., Woo, K. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.8448 · Cited by 1,064
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
Long, G. V., Menzies, A. M., Nagrial, A. M., Haydu, L. E., Hamilton, A. L., Mann, G. J., Hughes, T. M., Thompson, J. F., Scolyer, R. A., & Kefford, R. F. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.4327 · Cited by 1,042
Self-citationRAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
Su, F., Viros, A., Milagre, C., Trunzer, K., Bollag, G., Spleiss, O., Reis-Filho, J. S., Kong, X., Koya, R. C., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105358 · Cited by 1,038
Self-citationAscierto, P. A., McArthur, G. A., Dréno, B., Atkinson, V., Liszkay, G., Di Giacomo, A. M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30122-x · Cited by 1,022
Self-citationGoldberg, S. B., Gettinger, S. N., Mahajan, A., Chiang, A. C., Herbst, R. S., Sznol, M., Tsiouris, A. J., Cohen, J., Vortmeyer, A., Jilaveanu, L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30053-5 · Cited by 993
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Shi, H., Hugo, W., Kong, X., Hong, A., Koya, R. C., Moriceau, G., Chodon, T., Guo, R., Johnson, D. B., Dahlman, K. B., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0642 · Cited by 982
Self-citationMcArthur, G. A., Chapman, P. B., Robert, C., Larkin, J., Haanen, J. B., Dummer, R., Ribas, A., Hogg, D., Hamid, O., Ascierto, P. A., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70012-9 · Cited by 977
Self-citationHodi, F. S., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K. F., McDermott, D. F., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30366-7 · Cited by 968
Brichard, V, Van Pel, A., Wölfel, T., Wölfel, C., De Plaen, E., Lethé, B., Coulie, P., & Boon, T. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.2.489 · Cited by 950
Frederick, D. T., Piris, A., Cogdill, A. P., Cooper, Z. A., Lezcano, C., Ferrone, C. R., Mitra, D., Boni, A., Newton, L. P., Liu, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1630 · Cited by 944
Falchook, G. S., Long, G. V., Kurzrock, R., Kim, K. B., Arkenau, T. H., Brown, M. P., Hamid, O., Infante, J. R., Millward, M., Pavlick, A. C., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60398-5 · Cited by 943
Self-citationLong, G. V., Trefzer, U., Davies, M. A., Kefford, R. F., Ascierto, P. A., Chapman, P. B., Puzanov, I., Hauschild, A., Robert, C., Algazi, A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70431-x · Cited by 918
Self-citationThe Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Van Allen, E. M., Wagle, N., Sucker, A., Treacy, D. J., Johannessen, C. M., Goetz, E. M., Place, C. S., Taylor-Weiner, A., Whittaker, S., Kryukov, G. V., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0617 · Cited by 912
KIT as a Therapeutic Target in Metastatic Melanoma
Carvajal, R. D. (2011) · JAMA · doi:10.1001/jama.2011.746 · Cited by 888
Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF
Haq, R., Shoag, J., Andreu-Perez, P., Yokoyama, S., Edelman, H., Rowe, G. C., Frederick, D. T., Hurley, A. D., Nellore, A., Kung, A. L., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.003 · Cited by 818
An immune-active tumor microenvironment favors clinical response to ipilimumab
Ji, R.-R., Chasalow, S. D., Wang, L., Hamid, O., Schmidt, H., Cogswell, J., Alaparthy, S., Berman, D., Jure-Kunkel, M., Siemers, N. O., et al. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1172-6 · Cited by 775
Guo, J., Si, L., Kong, Y., Flaherty, K. T., Xu, X., Zhu, Y., Corless, C. L., Li, L., Li, H., Sheng, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.9275 · Cited by 688
Self-citationSelective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
Wilmott, J. S., Long, G. V., Howle, J. R., Haydu, L. E., Sharma, R. N., Thompson, J. F., Kefford, R. F., Hersey, P., & Scolyer, R. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2479 · Cited by 652
Self-citationAscierto, P. A., Schadendorf, D., Berking, C., Agarwala, S. S., van Herpen, C. M., Queirolo, P., Blank, C. U., Hauschild, A., Beck, J. T., St-Pierre, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70024-x · Cited by 640
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
Müller, J., Krijgsman, O., Tsoi, J., Robert, L., Hugo, W., Song, C., Kong, X., Possik, P. A., Cornelissen-Steijger, P. D. M., Foppen, M. H. G., et al. (2014) · Nature Communications · doi:10.1038/ncomms6712 · Cited by 639
Self-citationAdaptive Immune Resistance: How Cancer Protects from Immune Attack
Ribas, A. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0563 · Cited by 613
Self-citationHodi, F. S., Corless, C. L., Giobbie-Hurder, A., Fletcher, J. A., Zhu, M., Marino-Enriquez, A., Friedlander, P., Gonzalez, R., Weber, J. S., Gajewski, T. F., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7836 · Cited by 608
Self-citationNon-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
Hugo, W., Shi, H., Sun, L., Piva, M., Song, C., Kong, X., Moriceau, G., Hong, A., Dahlman, K. B., Johnson, D. B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.061 · Cited by 600
Self-citationRegulatory circuits of T cell function in cancer
Speiser, D. E., Ho, P.-C., & Verdeil, G. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.80 · Cited by 566
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma
Hu-Lieskovan, S., Mok, S., Homet Moreno, B., Tsoi, J., Robert, L., Goedert, L., Pinheiro, E. M., Koya, R. C., Graeber, T. G., Comin-Anduix, B., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4691 · Cited by 563
Self-citationPuzanov, I., Milhem, M. M., Minor, D., Hamid, O., Li, A., Chen, L., Chastain, M., Gorski, K. S., Anderson, A., Chou, J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1529 · Cited by 562
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
Lin, L., Sabnis, A. J., Chan, E., Olivas, V., Cade, L., Pazarentzos, E., Asthana, S., Neel, D., Yan, J. J., Lu, X., et al. (2015) · Nature Genetics · doi:10.1038/ng.3218 · Cited by 551
Self-citationParaiso, K. H. T., Xiang, Y., Rebecca, V. W., Abel, E. V., Chen, Y. A., Munko, A. C., Wood, E., Fedorenko, I. V., Sondak, V. K., Anderson, A. R. A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2954 · Cited by 551
Self-citationBRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
Rizos, H., Menzies, A. M., Pupo, G. M., Carlino, M. S., Fung, C., Hyman, J., Haydu, L. E., Mijatov, B., Becker, T. M., Boyd, S. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3122 · Cited by 547
Self-citationYao, Z., Torres, N. M., Tao, A., Gao, Y., Luo, L., Li, Q., de Stanchina, E., Abdel-Wahab, O., Solit, D. B., Poulikakos, P. I., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.08.001 · Cited by 543
A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors
Konieczkowski, D. J., Johannessen, C. M., Abudayyeh, O., Kim, J. W., Cooper, Z. A., Piris, A., Frederick, D. T., Barzily-Rokni, M., Straussman, R., Haq, R., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0424 · Cited by 535
Self-citationDisruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma.
Guldberg, P., Straten, P. T., Birck, A., Ahrenkiel, V., Kirkin, A. F., & Zeuthen, J. (1997) · PubMed · Cited by 480
Wagle, N., Van Allen, E. M., Treacy, D. J., Frederick, D. T., Cooper, Z. A., Taylor-Weiner, A., Rosenberg, M., Goetz, E. M., Sullivan, R. J., Farlow, D. N., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0631 · Cited by 478
Self-citationA melanocyte lineage program confers resistance to MAP kinase pathway inhibition
Johannessen, C. M., Johnson, L. A., Piccioni, F., Townes, A., Frederick, D. T., Donahue, M. K., Narayan, R., Flaherty, K. T., Wargo, J. A., Root, D. E., et al. (2013) · Nature · doi:10.1038/nature12688 · Cited by 452
Self-citationMenzies, A. M., Haydu, L. E., Visintin, L., Carlino, M. S., Howle, J. R., Thompson, J. F., Kefford, R. F., Scolyer, R. A., & Long, G. V. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0052 · Cited by 434
Self-citationLong, G. V., Fung, C., Menzies, A. M., Pupo, G. M., Carlino, M. S., Hyman, J., Shahheydari, H., Tembe, V., Thompson, J. F., Saw, R. P., et al. (2014) · Nature Communications · doi:10.1038/ncomms6694 · Cited by 375
Self-citationOncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
Kwong, L. N., Costello, J. C., Liu, H., Jiang, S., Helms, T. L., Langsdorf, A. E., Jakubosky, D., Genovese, G., Muller, F. L., Jeong, J. H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2941 · Cited by 358
Self-citationGray, E. S., Rizos, H., Reid, A. L., Boyd, S. C., Pereira, M. R., Lo, J., Tembe, V., Freeman, J., Lee, J. H. J., Scolyer, R. A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5788 · Cited by 336
Self-citationDranoff, G. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18813.x · Cited by 334
Weber, J. S., Gibney, G., Sullivan, R. J., Sosman, J. A., Slingluff, C. L., Lawrence, D. P., Logan, T. F., Schuchter, L. M., Nair, S., Fecher, L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30126-7 · Cited by 334
Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity?
Albino, A. P., Strange, R. L., Oliff, A. I., Furth, M. E., & Old, L. J. (1984) · Nature · doi:10.1038/308069a0 · Cited by 324
Johnson, D. B., Menzies, A. M., Zimmer, L., Eroglu, Z., Ye, F., Zhao, S., Rizos, H., Sucker, A., Scolyer, R. A., Gutzmer, R., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.08.022 · Cited by 323
Self-citationLong, G. V., Grob, J.-J., Nathan, P., Ribas, A., Robert, C., Schadendorf, D., Lane, S. R., Mak, C., Legenne, P., Flaherty, K. T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30578-2 · Cited by 315
Self-citationRibas, A., Gonzalez, R., Pavlick, A., Hamid, O., Gajewski, T. F., Daud, A., Flaherty, L., Logan, T., Chmielowski, B., Lewis, K., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70301-8 · Cited by 299
Self-citationDummer, R., Goldinger, S. M., Turtschi, C. P., Eggmann, N. B., Michielin, O., Mitchell, L., Veronese, L., Hilfiker, P. R., Felderer, L., & Rinderknecht, J. D. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.11.002 · Cited by 287
Missense mutations of the BRAF gene in human lung adenocarcinoma.
Naoki, K., Chen, T. H., Richards, W. G., Sugarbaker, D. J., & Meyerson, M. M. (2002) · PubMed · Cited by 287
Thomas, N. E., Busam, K. J., From, L., Kricker, A., Armstrong, B. K., Anton-Culver, H., Gruber, S. B., Gallagher, R. P., Zanetti, R., Rosso, S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.3002 · Cited by 284
Parmenter, T. J., Kleinschmidt, M., Kinross, K. M., Bond, S. T., Li, J., Kaadige, M. R., Rao, A., Sheppard, K. E., Hugo, W., Pupo, G. M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0440 · Cited by 283
Self-citationJäger, E., Ringhoffer, M., Karbach, J., Arand, M., Oesch, F., & Knuth, A. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960516)66:4<470::aid-ijc10>3.0.co;2-c · Cited by 278
Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma
Kong, Y., Si, L., Zhu, Y., Xu, X., Corless, C. L., Flaherty, K. T., Li, L., Li, H., Sheng, X., Cui, C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2346 · Cited by 251
Self-citationGajewski, T. F., Louahed, J., & Brichard, V. G. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eacbd8 · Cited by 250
Resistance to BRAF Inhibition in Melanomas
Solit, D. B., & Rosen, N. (2011) · New England Journal of Medicine · doi:10.1056/nejmcibr1013704 · Cited by 243
Greaves, W. O., Verma, S., Patel, K. P., Davies, M. A., Barkoh, B. A., Galbincea, J. M., Yao, H., Lazar, A. J., Aldape, K. D., Medeiros, L. J., et al. (2013) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2012.10.002 · Cited by 227
Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
Atefi, M., von Euw, E., Attar, N., Ng, C., Chu, C., Guo, D., Nazarian, R., Chmielowski, B., Glaspy, J. A., Comin-Anduix, B., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028973 · Cited by 227
Self-citationLarkin, J., Lao, C. D., Urba, W. J., McDermott, D. F., Horak, C., Jiang, J., & Wolchok, J. D. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1184 · Cited by 223
Ackerman, A., Klein, O., McDermott, D. F., Wang, W., Ibrahim, N., Lawrence, D. P., Gunturi, A., Flaherty, K. T., Hodi, F. S., Kefford, R., et al. (2014) · Cancer · doi:10.1002/cncr.28620 · Cited by 223
Self-citationHaq, R., Yokoyama, S., Hawryluk, E. B., Jönsson, G. B., Frederick, D. T., McHenry, K., Porter, D., Tran, T.-N., Love, K. T., Langer, R., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205575110 · Cited by 222
Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma
Flaherty, K. T., Lee, S. J., Zhao, F., Schuchter, L. M., Flaherty, L., Kefford, R., Atkins, M. B., Leming, P., & Kirkwood, J. M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.1529 · Cited by 221
Self-citationGoodall, J., Carreira, S., Denat, L., Kobi, D., Davidson, I., Nuciforo, P., Sturm, R. A., Larue, L., & Goding, C. R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1053 · Cited by 208
Santiago-Walker, A., Gagnon, R., Mazumdar, J., Casey, M., Long, G. V., Schadendorf, D., Flaherty, K., Kefford, R., Hauschild, A., Hwu, P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0321 · Cited by 206
Self-citationGopal, Y. N. V., Rizos, H., Chen, G., Deng, W., Frederick, D. T., Cooper, Z. A., Scolyer, R. A., Pupo, G., Komurov, K., Sehgal, V., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1392 · Cited by 201
Self-citationRibas, A., Robert, C., Hodi, F. S., Wolchok, J. D., Joshua, A. M., Hwu, W.-J., Weber, J. S., Zarour, H. M., Kefford, R., Loboda, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.3001 · Cited by 201
Self-citationBRAF L597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors
Dahlman, K. B., Xia, J., Hutchinson, K., Ng, C., Hucks, D., Jia, P., Atefi, M., Su, Z., Branch, S., Lyle, P. L., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0097 · Cited by 198
Self-citationNathanson, K. L., Martin, A.-M., Wubbenhorst, B., Greshock, J., Letrero, R., D'Andrea, K., O'Day, S., Infante, J. R., Falchook, G. S., Arkenau, H.-T., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0827 · Cited by 196
Self-citationZeng, G., Wang, X., Robbins, P. F., Rosenberg, S. A., & Wang, R.-F. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061507398 · Cited by 193
Luke, J. J., Callahan, M. K., Postow, M. A., Romano, E., Ramaiya, N., Bluth, M., Giobbie‐Hurder, A., Lawrence, D. P., Ibrahim, N., Ott, P. A., et al. (2013) · Cancer · doi:10.1002/cncr.28282 · Cited by 192
Self-citationRibas, A., Butler, M., Lutzky, J., Lawrence, D. P., Robert, C., Miller, W., Linette, G. P., Ascierto, P. A., Kuzel, T., Algazi, A. P., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.3003 · Cited by 158
Self-citationRecurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy
Botton, T., Yeh, I., Nelson, T. A., Vemula, S. S., Sparatta, A. J., Garrido, M. C., Allégra, M., Rocchi, S., Bahadoran, P., McCalmont, T. H., et al. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12148 · Cited by 147
BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth
Wang, T., Xiao, M., Ge, Y., Krepler, C., Belser, E., López-Coral, A., Xu, X., Zhang, G., Azuma, R., Liu, Q., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1554 · Cited by 146
Chemotherapy in the management of advanced cutaneous malignant melanoma
Luke, J. J., & Schwartz, G. K. (2013) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2012.08.016 · Cited by 145
Self-citationTORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF- Mutant Melanoma
Corcoran, R. B., Rothenberg, S. M., Hata, A. N., Faber, A. C., Piris, A., Nazarian, R. M., Brown, R. D., Godfrey, J. T., Winokur, D., Walsh, J., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005753 · Cited by 140
Self-citationGenomic alterations in spontaneous and carcinogen-induced murine melanoma cell lines
Melnikova, V. O., Bolshakov, S. V., Walker, C., & Ananthaswamy, H. N. (2004) · Oncogene · doi:10.1038/sj.onc.1207405 · Cited by 132
Kawakami, Y., Dang, N., Wang, X., Tupesis, J. P., Robbins, P. F., Wang, R., Wunderlich, J. R., Yannelli, J. R., & Rosenberg, S. A. (2000) · Journal of Immunotherapy · doi:10.1097/00002371-200001000-00004 · Cited by 124
Long, G. V., Dummer, R., Ribas, A., Puzanov, I. J., Vanderwalde, A. M., Andtbacka, R. H. I., Michielin, O. A., Olszanski, A. J., Malvehy, J., Cebon, J. S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.9568 · Cited by 124
Self-citationIsolation and Molecular Characterization of Circulating Melanoma Cells
Luo, X., Mitra, D., Sullivan, R. J., Wittner, B. S., Kimura, A. M., Pan, S., Hoang, M. P., Brannigan, B. W., Lawrence, D. P., Flaherty, K. T., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.039 · Cited by 119
Self-citationKinase-Impaired BRAF Mutations in Lung Cancer Confer Sensitivity to Dasatinib
Sen, B., Peng, S., Tang, X., Erickson, H. S., Galindo, H., Mazumdar, T., Stewart, D. J., Wistuba, I. I., & Johnson, F. M. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003513 · Cited by 119
Plimack, E. R., Joaquim Bellmunt, B., Gupta, S., Berger, R., Montgomery, B., Heath, K., Juco, J. W., Emancipator, K., Pathiraja, K., Lunceford, J. K., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.4502 · Cited by 115
BRAF inhibitor activity in V600R metastatic melanoma
Klein, O., Clements, A., Menzies, A. M., O'Toole, S. A., Kefford, R. F., & Long, G. V. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.11.004 · Cited by 114
Self-citationTalimogene Laherparepvec for the Treatment of Advanced Melanoma
Ott, P. A., & Hodi, F. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2709 · Cited by 111
Robert, C., Ribas, A., Hamid, O., DAUD, A. I., Wolchok, J. D., Joshua, A. M., Hwu, W., Weber, J. S., Gangadhar, T. C., Joseph, R. W., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.9503 · Cited by 108
Self-citationAscierto, P. A., Simeone, E., Chiarion‐Sileni, V., Vecchio, M. D., Marchetti, P., Cappellini, G. C. A., Ridolfi, R., Rosa, F. D., Cognetti, F., Ferraresi, V., et al. (2014) · Cancer Investigation · doi:10.3109/07357907.2014.885984 · Cited by 103
Luke, J. J., & Hodi, F. S. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0391 · Cited by 100
Self-citationRobert, C., Karaszewska, B., Schachter, J., Rutkowski, P. L., Mackiewicz, A. A., Stroyakovskiy, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · European Journal of Cancer · doi:10.1016/s0959-8049(16)31820-2 · Cited by 81
Kim, H., Frederick, D. T., Levesque, M. P., Cooper, Z. A., Feng, Y., Krepler, C., Brill, L. M., Samuels, Y., Hayward, N. K., Perlina, A., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.049 · Cited by 79
Self-citationBRAF and MEK inhibition in melanoma
Dossett, L. A., Kudchadkar, R. R., & Zager, J. S. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1011618 · Cited by 79
p53 Rescue through HDM2 Antagonism Suppresses Melanoma Growth and Potentiates MEK Inhibition
Ji, Z., Njauw, C.-N. J., Taylor, M., Neel, V., Flaherty, K. T., & Tsao, H. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.313 · Cited by 78
Self-citationGangadhar, T. C., Hamid, O., Smith, D. C., Bauer, T. M., Wasser, J. S., Luke, J. J., Balmanoukian, A. S., Kaufman, D. R., Zhao, Y., Maleski, J. E., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-3-s2-o7 · Cited by 77
Self-citationTargeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma
Carlino, M. S., Long, G. V., Kefford, R. F., & Rizos, H. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.021 · Cited by 75
Self-citationCoit, D. G., Andtbacka, R. H. I., Anker, C. J., Bichakjian, C. K., Carson, W. E., DAUD, A. I., Dilawari, R. A., DiMaio, D. J., Guild, V., Halpern, A. C., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0036 · Cited by 69
Schachter, J., Ribas, A., Long, G. V., Arance, A. M., Grob, J., Mortier, L., DAUD, A. I., Carlino, M. S., McNeil, C. M., Lotem, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.9504 · Cited by 68
Self-citationFlaherty, K. T., Davies, M. A., Grob, J., Long, G. V., Nathan, P., Ribas, A., Robert, C., Schadendorf, D., Frederick, D. T., Hammond, M. R., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.9502 · Cited by 66
Self-citationHarada, M., Li, Y. F., El‐Gamil, M., Rosenberg, S. A., & Robbins, P. F. (2001) · PubMed · Cited by 64
Cooper, Z. A., Reuben, A., Spencer, C. N., Prieto, P. A., Austin-Breneman, J. L., Jiang, H., Haymaker, C., Gopalakrishnan, V., Tetzlaff, M. T., Frederick, D. T., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1136044 · Cited by 60
Self-citationSeiwert, T. Y., Burtness, B. A., Weiss, J., Eder, J. P., Yearley, J. H., Murphy, E., Nebozhyn, M., McClanahan, T., Ayers, M., Lunceford, J. K., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.6017 · Cited by 54
Frederick, D. T., Fragomeni, R. A. S., Schalck, A. P., Ferreiro-Neira, I., Hoff, T., Cooper, Z. A., Haq, R., Panka, D. J., Kwong, L. N., Davies, M. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101286 · Cited by 52
Self-citationLong, G. V., Atkinson, V. G., Cebon, J. S., Jameson, M. B., Fitzharris, B. M., McNeil, C. M., Hill, A. G., Ribas, A., Atkins, M. B., Thompson, J. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.9506 · Cited by 49
Self-citationRibas, A., Hodi, F. S., Lawrence, D. P., Atkinson, V. G., Starodub, A., Carlino, M. S., Fisher, R. A., Long, G. V., Miller, W. H., Huang, Y., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3014 · Cited by 47
Self-citationVallacchi, V., Vergani, E., Camisaschi, C., Deho, P., Cabras, A. D., Sensi, M., Cecco, L. D., Bassani, N., Ambrogi, F., Carbone, A., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1672 · Cited by 39
Simultaneous suppression of MITF and BRAFV600E enhanced inhibition of melanoma cell proliferation
Kido, K., Sumimoto, H., Asada, S., Okada, S., Yaguchi, T., Kawamura, N., Miyagishi, M., Saida, T., & Kawakami, Y. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01266.x · Cited by 37
Hwu, P., Hamid, O., Gonzalez, R. C., Infante, J. R., Patel, M. R., Hodi, F. S., Lewis, K. D., Wallin, J. J., Mwawasi, G., Cha, E., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw379.05 · Cited by 37
Larkin, J., Chiarion‐Sileni, V., González, R., Grob, J., Cowey, C. L., Lao, C. D., Wagstaff, J., Hogg, D., Hill, A., Carlino, M. S., et al. (2015) · European Journal of Cancer · doi:10.1016/s0959-8049(16)31822-6 · Cited by 36
Joseph, R. W., Elassaiss‐Schaap, J., Wolchok, J. D., Joshua, A. M., Ribas, A., Hodi, F. S., Hamid, O., Robert, C., DAUD, A. I., Hwu, W., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.3015 · Cited by 35
Self-citationProgression-free survival landmark analysis: a critical endpoint in melanoma clinical trials
Ascierto, P. A., & Long, G. V. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30017-1 · Cited by 32
Self-citationMangana, J., Cheng, P. F., Schindler, K., Weide, B., Held, U., Frauchiger, A. L., Romano, E., Kähler, K. C., Rozati, S., Rechsteiner, M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139438 · Cited by 31
BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma
Richman, J., Martín-Liberal, J., Diem, S., & Larkin, J. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1044971 · Cited by 29
Shankaran, V., Muro, K., Bang, Y., Geva, R., Catenacci, D. V. T., Gupta, S., Eder, J. P., Berger, R., Loboda, A. P., Albright, A. V., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.3026 · Cited by 25
Ascierto, P. A., Vecchio, M. D., Robert, C., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw379.01 · Cited by 24
DAUD, A. I., Weber, J. S., Sosman, J. A., Kim, K., Gonzalez, R. C., Hamid, O., Infante, J. R., Cebon, J. S., Schuchter, L. M., Long, G. V., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.9036 · Cited by 22
Self-citationLyle, M. K., Lee, J., Menzies, A. M., Chan, M. M. K., Clements, A., Carlino, M. S., Kefford, R. F., & Long, G. V. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.9077 · Cited by 21
Self-citationTsai, K. K., Shoushtari, A. N., Munhoz, R. R., Eroglu, Z., Piulats, J. M., Ott, P. A., Johnson, D. B., Hwang, J. J., DAUD, A. I., Sosman, J. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.9507 · Cited by 7
Cited by
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Long, G. V., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708539 · Cited by 1,490
Self-citationAnnual Report to the Nation on the Status of Cancer, part I: National cancer statistics
Cronin, K. A., Lake, A. J., Scott, S., Sherman, R. L., Noone, A., Howlader, N., Henley, S. J., Anderson, R. N., Firth, A. U., Ma, J., et al. (2018) · Cancer · doi:10.1002/cncr.31551 · Cited by 1,485
Current state of immunotherapy for glioblastoma
Lim, M., Xia, Y., Bettegowda, C., & Weller, M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0003-5 · Cited by 1,365
Tsoi, J., Robert, L., Paraiso, K., Galvan, C., Sheu, K. M., Lay, J., Wong, D. J. L., Atefi, M., Shirazi, R., Wang, X., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.017 · Cited by 938
Self-citationAnnual report to the nation on the status of cancer, part I: National cancer statistics
Henley, S. J., Ward, E. M., Scott, S., Ma, J., Anderson, R. N., Firth, A. U., Thomas, C. C., Islami, F., Weir, H. K., Lewis, D. R., et al. (2020) · Cancer · doi:10.1002/cncr.32802 · Cited by 853
Metadata
- Authors
- Luke, J. J., Flaherty, K. T., Ribas, A., & Long, G. V.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2017-04-04
- Volume
- 14
- Issue
- 8
- Pages
- 463-482
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W2605233023
- Cited by
- 1,254
- References
- 166
- FWCI
- 9.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.